New Paradigms for Treatment and Management of Retinal Vein Occlusion (RVO)

Complimentary

Released on June 14, 2021
Expires on June 14, 2022

Categories: , , , , , , , , , , ,
Close-up of a human eye with a retinal scan overlay and an inset image of the retina.

Start Activity

Program Description

The activity is designed to provide the latest data in diagnosis and give real-world examples and recommendations for retinal vein occlusion treatment. Focusing on biologic agents, this program will highlight retinal vein occlusion treatment options, including indications, efficacy, and safety of the currently available and emerging agents. Challenges encountered in the treatment of retinal vein occlusion will also be highlighted. Treatment of retinal vein occlusion with intravitreal anti-VEGF, the long-running standard of care, is limited by a need for frequent repeat injections to derive optimal visual outcomes. The high treatment burden is associated with undertreatment, contributing to the suboptimal visual effects observed in the real world versus clinical trials. This educational activity will familiarize the need for early diagnosis and treatment, new data to optimize the use of novel agents currently available.

Intended Audience

This webcast is designed to meet the educational needs of ophthalmologists, primary care physicians for prompt referral to ophthalmologists, retina specialists, optometrists, nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in treating retinal vein occlusion (RVO).

Commercial Supporter

Supported by Regeneron Pharmaceuticals, Inc.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Analyze the pathophysiology and diagnosis of retinal vein occlusion (RVO) with special emphasis on integrating novel optical coherence tomography (OCT) algorithms into clinical practice
  • Recognize the individualizing therapy with anti-VEGF inhibitors and intravitreal dexamethasone implant for optimal patient outcomes in patients with RVO
  • Outline upcoming clinical trials of novel therapies for RVO

Accredited Providers

Jointly provided by Amedco, a CME/CE company and MedNet


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet, LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA PRA Category 1 Credit(s)TM

Designation Statement

Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Contact Hour(s)

Designation Statement

Amedco LLC designates this enduring material activity for a maximum of 1.50 ANCC contact hours.

Additional Credit Information

Note to Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.50 hours.

Note to Physician Assistants
AAPA accepts AMA PRA Category 1 Credit(s)™ for the PRA from organizations accredited by ACCME. Maximum of 1.50 hours.

Planners and Managers Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE webcast:

Dr. Khanani discloses that he is a consultant of Novartis, Allergan and Genentech
Kamatham A. Naidu, PhD (MedNet), has no relevant financial relationships to disclose.
Brian Waggoner (MedNet, LLC) has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Conflicts of Interest Policy

It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Disclosure of Unlabeled Use

It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Non-Endorsement of Products

Amedco does not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Faculty

Caroline R. Baumal, MD
Associate Professor of Ophthalmology
Tufts University School of Medicine
Boston, MA

Dr. Baumal discloses that she is a consultant of Genentech, Novartis, Zeiss, Ora, Eyepoint

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno School of Medicine
Reno, NV

Dr. Khanani discloses that he is a consultant of Novartis, Allergan and Genentech.

Instructions

There are no fees for participating and receiving CME/CE credit for this webcast. During the period June 14, 2021 through June 14, 2022, participants must read all the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CME/CE Provider at certificate@amedcoemail.com.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

Amedco observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

Webcast

Time to Complete: 1.50 hours

Released: June 14, 2021

Expires: June 14, 2022

Maximum Credits:
1.50 / AMA PRA Category 1 Credit(s)TM
1.50 / ANCC Contact Hour(s)

Related products